

NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Sovaldi

Beneficiary Information		
1. Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:
Prescriber Information		_
7. Requester Contact Information	n	
•	Phone #:	Ext.
Drug Information		
8. Drug Name:	9. Strength:	10. Quantity Per 30 Days: Weeks
11. Length of Therapy (in days):	☐ 12 Weeks ☐ 24 Weeks ☐ 48 V	Veeks
Clinical Information		
Total Length of Therapy (Check		
		perienced adult beneficiaries without cirrhosis -naïve and treatment-experienced pediatric
	without cirrhosis or with compensated ci	
	n containing an NS3/4A PI ₂ without prior t	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
		eligible; genotype 3 for treatment-naïve and
	hout cirrhosis or with compensated cirrho	
	xperienced pediatric patients, 3 years of	age or older, without cirrhosis or with
compensated cirrhosis (child-pug	•	
		sis of Hepatocellular Carcinoma awaiting liver
transplantation (up to 46 weeks t	or until liver transplantation, whichever co	ones ilist)
1. Does the beneficiary have a d	iagnosis of chronic hepatitis C infections	with one of the following confirmed diagnosis':
☐ Genotype 1 or 4 without cir	rrhosis or with compensated cirrhosis and	beneficiary is 18years of age or older
☐ Genotype 2 or 3 without cir	rrhosis or with compensated cirrhosis and	beneficiary is 3 years of age or older
•	tion with hepatocellular carcinoma awaitir	•
	• •	with genotype and subtype being submitted
	**Lab test results MUST be attached to	
_	•	seline that was tested within the past 6 months
	d)? □ Yes □ No HCN RNA (IU/mI): onably certain that treatment will improve	
☐ Yes ☐ No	mably certain that treatment will improve	the beneficiary 3 overall fleath status:
	combination with ribavirin and pegylated	interferon alfa for genotypes 1 and 4?
□ Yes □ No	1 37	3 71
		es with genotype 1 who are peginterferon-
•	entation of previous peginterferon therap	y or reason for ineligibility must be submitted
for review)? ☐ Yes ☐ No		0 and 0 and 4 arts 01101 5
• .	combination with ribavirin for genotypes	2 and 3 and/or in CHC beneficiaries with
hepatocellular carcinoma awaitin	•	
8. Is Sovaldi being used as mono	outerapy: Lites Lite	



9. Is Sovaldi being used with any other sofosvuvir containi	
10. Does the beneficiary have any FDA labeled contraindi	cations to sofosbuvir (Sovaldi)? ☐ Yes ☐ No
11. Is the beneficiary pregnant? ☐ Yes ☐ No	
12. Does the beneficiary have severe renal impairment (C	rCl less than 30 mL/min), end stage renal disease, or require
dialysis (AASLD/IDSA 2014)? □ Yes □ No	
13. Is the beneficiary a non-responder to sofosbuvir? □ Y	es □ No
14. Has the beneficiary previously failed therapy with a tre	atment regimen that included sofosbuvir? Yes No
15. Does the beneficiary have hepatocellular carcinoma a	nd is not awaiting a liver transplant? □ Yes □ No
Signature of Prescriber:	Date:
(Prescriber Signature Mandatory)	
I coutiful that the information provided is accurate and aspeal	lata ta tha baat of way kwayyladaa awal luwalawatawal that awy

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Please fax this form to 1-800-678-3189 Pharmacy PA Call Center: 1-866-799-5318